Neurology News

AstraZeneca has announced FDA approval of Ultomiris, a long-acting C5 complement inhibitor for the treatment of adults with generalized myasthenia gravis.

The FDA and European Commission have both granted orphan drug designation to AviadoBio for its new gene therapy to treat frontotemporal dementia, according to a company press release.

Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with CDKL5 deficiency disorder, according to a study published in The Lancet Neurology.

People with familial hypercholesterolemia and those on long-term, high-intensity statins had no greater risk for dementia than matched controls, per a study published in JAMA Network Open.

The benefits of ticagrelor and aspirin outweighed the risk for major hemorrhage in patients with mild to moderate ischemic stroke or at high risk for transient ischemic attack during 30 days of treatment, according to a Neurology study.

DENVER — Selective impairments in regional fetal brain growth predicted adverse development among infants with congenital heart disease, according to study findings presented at the Pediatric Academic Societies Meeting.

Those with amnestic mild cognitive impairment who used the BrainHQ app for visual speed and attention exercises improved neuropsychological measures of speed, attention, memory and connectivity.

The FDA has granted breakthrough device designation to Quanterix Corp. for its Simoa neurofilament light chain plasma test, a prognostic aid that assesses risk for disease activity in patients with relapsing-remitting MS.

Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.

A collaboration between Mayo Clinic researchers and a team dedicated to researching frontotemporal dementia has identified neurofilament light as a useful biomarker for the disease.